Literature DB >> 6141748

Vecuronium-induced neuromuscular blockade during enflurane, isoflurane, and halothane anesthesia in humans.

S M Rupp, R D Miller, P J Gencarelli.   

Abstract

To determine the effect of the commonly used volatile anesthetics on a vecuronium-induced neuromuscular blockade, the authors studied 54 patients anesthetized with 1.2 MAC or 2.2 MAC enflurane, isoflurane, or halothane (MAC value includes contribution from 60% nitrous oxide). During 1.2 MAC enflurane, isoflurane, and halothane, the ED50S (the doses depressing twitch tension 50%) for vecuronium were 12.8, 14.7, and 16.9 micrograms/kg, respectively. During 2.2 MAC enflurane, isoflurane, and halothane, the ED50S for vecuronium were 6.3, 9.8, and 13.8 micrograms/kg, respectively (P less than 0.05). Time from injection to peak effect was the same for each anesthetic group (6.5 +/- 0.5 min, mean +/- SD), except for the group given 2.2 MAC enflurane (9.7 +/- 0.6 min) (P less than 0.05). The duration of a 50% block from injection to 90% recovery was the same for each group (mean 20 +/- 4 min), except for the group given 2.2 MAC enflurane (46.5 min) (P less than 0.05). The authors conclude that enflurane is the most potent volatile anesthetic, followed by isoflurane and then halothane, in augmenting a vecuronium-induced neuromuscular blockade. Increasing the concentration of volatile anesthetic has less effect on a neuromuscular blockade produced by vecuronium than on one produced by other nondepolarizing relaxants (e.g., pancuronium and d-tubucurarine).

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6141748     DOI: 10.1097/00000542-198402000-00004

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  22 in total

Review 1.  A simulation of neuromuscular function and heart rate during induction, maintenance, and reversal of neuromuscular blockade.

Authors:  R R Jaklitsch; D R Westenskow
Journal:  J Clin Monit       Date:  1990-01

Review 2.  Drug interactions with neuromuscular blockers.

Authors:  S Feldman; L Karalliedde
Journal:  Drug Saf       Date:  1996-10       Impact factor: 5.606

3.  Pharmacokinetic-pharmacodynamic modeling of doxacurium: effect of input rate.

Authors:  Y Zhu; G Audibert; F Donati; F Varin
Journal:  J Pharmacokinet Biopharm       Date:  1997-02

4.  Reply.

Authors:  A Sidi
Journal:  Can J Anaesth       Date:  1992-04       Impact factor: 5.063

5.  Vecuronium is more potent in Montreal than in Paris.

Authors:  P Fiset; F Donati; P Balendran; C Meistelman; E Lira; D R Bevan
Journal:  Can J Anaesth       Date:  1991-09       Impact factor: 5.063

6.  Nitrous oxide potentiates vecuronium neuromuscular blockade in humans.

Authors:  P Fiset; P Balendran; D R Bevan; F Donati
Journal:  Can J Anaesth       Date:  1991-10       Impact factor: 5.063

Review 7.  Clinical pharmacokinetics of the inhalational anaesthetics.

Authors:  O Dale; B R Brown
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

8.  The neuromuscular effects of sevoflurane and isoflurane alone and in combination with vecuronium or atracurium in the rat.

Authors:  Y S Shin; R D Miller; J E Caldwell; E I Eger
Journal:  J Anesth       Date:  1992-01       Impact factor: 2.078

9.  A close relationship between post-tetanic twitch and train-of-four responses during neuromuscular blockade by vecuronium.

Authors:  H Toyooka; Y Noguchi; T Ebata; K Amaha
Journal:  J Anesth       Date:  1991-04       Impact factor: 2.078

10.  Potentiation of pancuronium and vecuronium neuromuscular blockade by intravenous salbutamol.

Authors:  Y Salib; F Donati
Journal:  Can J Anaesth       Date:  1993-01       Impact factor: 5.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.